{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"d-2-hydroxyglutaric-aciduria","columns":[{"gene":"","key":"population-6b1b5ab54941ccc47f2f","label":"D-2-hydroxyglutaric aciduria","mondoId":"MONDO:0010924","onsetQualifier":null,"originColumnKey":"MONDO:0010924/ORPHA:79315","originalViews":[{"key":"MONDO:0010924/ORPHA:79315","label":"D-2-hydroxyglutaric aciduria","scopeLabel":"ORPHA:79315","sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"recordKeys":["035c47b8e86e1f516590aa3b6f041a63ff1660d0781646ed508b4c96eefca901","0a2ef90cc757c5e2565d1e46f5c64b4218a89347188e8109a7282c65a3ea63cd","697b5b9dae8d260c881dd53cb84ab0afc025a91c32d46fc6a4ff81a994365bc0","719c762cbda379d8d6c30523ec3dfb4604ca18aa1f0ea5daa944f1ecc7d2bde6","7777534820a2af7c7d4a2fa70ba2ab0463af4ea9c988c1c61b0f2c4ca37aed67","8e3497ec4e741c0fa6adbf7c41fc9066bb1ceb7f95436f7cb6d48817a200e6da","a937196f88049a9e46eb193b822db772e5072907fcfc5330b35e3a93c02946c9","ae0c6f50d28b12f0e6dbb222c686595d1d66416cc6ca475c51e6acad27f4a3a0","c4ceeb5505cb3f48c6b88a1c989ba9c4df2298a788fdc6e9a6a136b649ef6c86","ca45862c99a8f75a3d8f584213b4a40837bb0edca3b0808a09d30d229de07496","cab1c4d57d23147e038fc8800f3196a6032cad71ce3b6bda29872d6d138caee6","caf202c969fc61cfd0638d1eb502f875d578c4aeb522afce79b6aab84fbb3b7a","f5a9038d4b9cb1c65d369e52fb94a1cd25d60b6e1e3c3890fe458b7e1cd5a59d"],"recordQualifiers":{},"scopeLabel":"ORPHA:79315","sourceIds":["ORPHA:79315"],"sourceScope":"Native source population. Existing approved source identity; no family evidence is inherited."}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-6b1b5ab54941ccc47f2f"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0001638","HP:0100704","HP:0040146","HP:0012321","HP:0012448","HP:0000750","HP:6000246"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":0,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":13,"sourceGroups":{"orphanet":13}},"features":[{"hpoId":"HP:0001638","label":"Cardiomyopathy","primary":true},{"hpoId":"HP:0100704","label":"Cerebral visual impairment","primary":true},{"hpoId":"HP:0040146","label":"D-2-hydroxyglutaric acidemia","primary":true},{"hpoId":"HP:0012321","label":"D-2-hydroxyglutaric aciduria","primary":true},{"hpoId":"HP:0012448","label":"Delayed myelination","primary":true},{"hpoId":"HP:0000750","label":"Delayed speech and language development","primary":true},{"hpoId":"HP:6000246","label":"Elevated CSF D-2-hydroxyglutaric acid concentration","primary":true},{"hpoId":"HP:0001298","label":"Encephalopathy","primary":false},{"hpoId":"HP:0001263","label":"Global developmental delay","primary":false},{"hpoId":"HP:0001252","label":"Hypotonia","primary":false},{"hpoId":"HP:0001250","label":"Seizure","primary":false},{"hpoId":"HP:0010307","label":"Stridor","primary":false},{"hpoId":"HP:0002119","label":"Ventriculomegaly","primary":false}],"ledeHtml":"D-2-alpha hydroxyglutaric aciduria is an inherited metabolic condition that is associated with progressive brain damage. Signs and symptoms of this condition include developmental delay, seizures, hypotonia, and abnormalities in the largest part of the brain (the cerebrum), which controls many important functions such as muscle movement, speech, vision, thinking, emotion, and memory. D-2-alpha hydroxyglutaric aciduria is caused by changes in the D2HGDH gene and is inherited in an autosomal recessive manner.","mondoId":"MONDO:0010924","node":{"canonicalSlug":"d-2-hydroxyglutaric-aciduria","comparisons":[{"documentSha256":"b29370411275f295db7fdff6e555648ed24bbddfdeb5b5354f7ca9857af0dcfa","key":"legacy-2-hydroxyglutaric-aciduria","kind":"legacy","label":"2-hydroxyglutaric aciduria","memberIds":["MONDO:0009370","MONDO:0010924","MONDO:0013345","MONDO:0014072","MONDO:0016001","MONDO:0024554"],"mondoId":"MONDO:0016001","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/2-hydroxyglutaric-aciduria.b29370411275f295db7fdff6e555648ed24bbddfdeb5b5354f7ca9857af0dcfa.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":[],"contentForm":"summary","independentCorroborationEstablished":false,"matchMethod":"automatic-identity-and-attribution","name":"D-2-hydroxyglutaric aciduria","originalSourceId":"ORPHA:79315","paragraphs":["D-2-alpha hydroxyglutaric aciduria is an inherited metabolic condition that is associated with progressive brain damage. Signs and symptoms of this condition include developmental delay, seizures, hypotonia, and abnormalities in the largest part of the brain (the cerebrum), which controls many important functions such as muscle movement, speech, vision, thinking, emotion, and memory. D-2-alpha hydroxyglutaric aciduria is caused by changes in the D2HGDH gene and is inherited in an autosomal recessive manner."],"rawAttribution":"MONDO:0010924","reviewed":null,"scope":"exact","source":"GARD","sourceRelease":"2026-10-25T03:39:31Z","upstream":"GARD:0005661","url":"https://rarediseases.info.nih.gov/diseases/5661"},"ownColumnKeys":["population-6b1b5ab54941ccc47f2f"],"publication":"published","relationships":[{"kind":"parent","label":"2-hydroxyglutaric aciduria","mondoId":"MONDO:0016001","slug":"2-hydroxyglutaric-aciduria"},{"kind":"child","label":"d-2-hydroxyglutaric aciduria 2","mondoId":"MONDO:0013345","slug":"d-2-hydroxyglutaric-aciduria-2"},{"kind":"child","label":"D-2-hydroxyglutaric aciduria 1","mondoId":"MONDO:0024554","slug":"d-2-hydroxyglutaric-aciduria-1"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[],"translation":"published"},"records":[{"frequencyKind":"range","key":"035c47b8e86e1f516590aa3b6f041a63ff1660d0781646ed508b4c96eefca901","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0001263","is_excluded":false,"label":"Global developmental delay","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"0a2ef90cc757c5e2565d1e46f5c64b4218a89347188e8109a7282c65a3ea63cd","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0002119","is_excluded":false,"label":"Ventriculomegaly","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"697b5b9dae8d260c881dd53cb84ab0afc025a91c32d46fc6a4ff81a994365bc0","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0000750","is_excluded":false,"label":"Delayed speech and language development","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"719c762cbda379d8d6c30523ec3dfb4604ca18aa1f0ea5daa944f1ecc7d2bde6","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001298","is_excluded":false,"label":"Encephalopathy","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"7777534820a2af7c7d4a2fa70ba2ab0463af4ea9c988c1c61b0f2c4ca37aed67","raw":{"aspect":"P","body_system":"musculoskeletal","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001252","is_excluded":false,"label":"Hypotonia","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"8e3497ec4e741c0fa6adbf7c41fc9066bb1ceb7f95436f7cb6d48817a200e6da","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0012448","is_excluded":false,"label":"Delayed myelination","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"a937196f88049a9e46eb193b822db772e5072907fcfc5330b35e3a93c02946c9","raw":{"aspect":"P","body_system":"eye","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0100704","is_excluded":false,"label":"Cerebral visual impairment","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"ae0c6f50d28b12f0e6dbb222c686595d1d66416cc6ca475c51e6acad27f4a3a0","raw":{"aspect":"P","body_system":"respiratory","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0010307","is_excluded":false,"label":"Stridor","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"c4ceeb5505cb3f48c6b88a1c989ba9c4df2298a788fdc6e9a6a136b649ef6c86","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040283","hpo_id":"HP:0001638","is_excluded":false,"label":"Cardiomyopathy","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"ca45862c99a8f75a3d8f584213b4a40837bb0edca3b0808a09d30d229de07496","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0040146","is_excluded":false,"label":"D-2-hydroxyglutaric acidemia","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"cab1c4d57d23147e038fc8800f3196a6032cad71ce3b6bda29872d6d138caee6","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:0012321","is_excluded":false,"label":"D-2-hydroxyglutaric aciduria","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"caf202c969fc61cfd0638d1eb502f875d578c4aeb522afce79b6aab84fbb3b7a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040282","hpo_id":"HP:0001250","is_excluded":false,"label":"Seizure","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]},{"frequencyKind":"range","key":"f5a9038d4b9cb1c65d369e52fb94a1cd25d60b6e1e3c3890fe458b7e1cd5a59d","raw":{"aspect":"P","body_system":"metabolic","disease_id":"ORPHA:79315","disease_name":"D-2-hydroxyglutaric aciduria","evidence":"TAS","frequency_raw":"HP:0040281","hpo_id":"HP:6000246","is_excluded":false,"label":"Elevated CSF D-2-hydroxyglutaric acid concentration","onset_id":null,"reference":"ORPHA:79315","source_release":"2026-06-23"},"sourceGroups":["orphanet"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/5661\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0010924\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>automatic-identity-and-attribution</dd><dt>Upstream attribution</dt><dd>GARD:0005661</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>D-2-alpha hydroxyglutaric aciduria is an inherited metabolic condition that is associated with progressive brain damage. Signs and symptoms of this condition include developmental delay, seizures, hypotonia, and abnormalities in the largest part of the brain (the cerebrum), which controls many important functions such as muscle movement, speech, vision, thinking, emotion, and memory. D-2-alpha hydroxyglutaric aciduria is caused by changes in the D2HGDH gene and is inherited in an autosomal recessive manner.</p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/5661\" rel=\"noreferrer\">GARD</a></p>","key":"overview","title":"Overview"}],"sharedSources":[],"slug":"d-2-hydroxyglutaric-aciduria","sourceDocuments":[{"name":"GARD: D-2-hydroxyglutaric aciduria","reviewed":null,"source_release":"2026-10-25T03:39:31Z","url":"https://rarediseases.info.nih.gov/diseases/5661"},{"name":"MONDO: D-2-hydroxyglutaric aciduria","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0010924"}],"sourceNote":"","synonyms":["D-2-HGA","D-2-hydroxyglutaric acidemia","D-2-hydroxyglutaric aciduria 1","D-2-hydroxyglutaric aciduria type 1","D2HA","D2HGA"],"takeawayHtml":"","title":"D-2-hydroxyglutaric aciduria"},"schemaVersion":1}
